LBT Innovations (ASX:LBT) signed an agreement to sell five Automated Plate Assessment System (APAS) Independence instruments to AstraZeneca and provide maintenance and support services over seven years in a deal valued at AU$3.4 million to AU$4.1 million, according to a Wednesday filing with the Australian bourse.

The APAS instruments use artificial intelligence and machine learning software to automate the imaging, analysis, and interpretation of microbiology culture plates. They will be installed within the next six months, with a potential for additional orders, the filing said.

The medical technology company's shares climbed over 33% in recent trade.

Price (AUD): $0.02, Change: $+0.01, Percent Change: +33.33%